In the race to finding a cure for COVID-19, Tychan Pte Ltd became the first in Singapore to kick off human clinical trials for a COVID-19 monoclonal antibody, taking only 4 months to do so!!
Tychan, a former A*StartCentral incubated start-up, has proven its ability to bring therapeutics to clinical trials in record speed - all this without the capital or resources of a large pharmaceutical.
In this session, Prof Ooi Eng Eong, co-founder of Tychan and Professor & Deputy Director of Programme in Emerging Infectious Diseases, Duke-NUS Medical School, shared with us his invaluable experiences and perspectives on how one can respond to diseases in real-time, and what enables them to overcome the odds.
This session was jointly organised by Hello Tomorrow Singapore and A*StartCentral.